BN Business News
أضف شركتك →
تجري حاليًا ترجمة هذا المقال. نعرض مؤقتًا النسخة الأصلية باللغة الإنجليزية.

التنظيم والقانون · 17‏/10‏/20001 دقائق للقراءة

Prospective Grant of Exclusive License: Insulin Producing Cells Differentiated from Non-Insulin Producing Cells by GLP-1 and Exendin-4 and Use Thereof

ترجمة آلية محلية · اللغة الأصلية للمصدر

الملخص

This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i), that the National Institutes of Health (NIH), Department of Health and Human Services, is contemplating the grant of an exclusive license worldwide to practice the invention embodied in: PCT Patent Application Serial Number PCT/US99/180899 (PHS Ref. E-151- 97/1) entitled "Insulin Producing Cells Differentiated from Non- Insulin Producing Cells by GLP-1 and Exendin-4 and Use Thereof" filed on August 18, 1999, claiming priority of August 10, 1998, to Amylin Pharmaceuticals, Inc., having a place of business in San Diego, CA. The patent rights in this invention have been assigned to the United States America.

اللغة الأصلية للمصدر: Federal Register — All Documentsافتح البيان الأصلي →

استكشف الموضوعات

تحليلات الأعمال →